1-Year Real-World Outcomes With the Amulet Occluder From the EMERGE LAA Postapproval Study
JACC: Cardiovascular Interventions · 2026-05 · 19 (9) · 1139-1151
DOI: 10.1016/j.jcin.2026.02.016 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JACC: Cardiovascular Interventions, 2026-05. Verfasst von Dhanunjaya Lakkireddy und 9 weiteren Autor:innen. Beteiligte Einrichtung: Kansas City Heart Rhythm Institute and Research Foundation, Overland Park, Kansas, USA. Electronic address: dhanunjaya.lakkireddy@hcahealthcare.com. Hauptthemen laut MEDLINE: Atrial Fibrillation, Left Atrial Appendage Closure, Septal Occluder Device. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: Abbott Laboratories.
Abstract (Originalsprache)
BACKGROUND: The Amulet occluder is indicated to reduce the risk for thrombus embolization from the left atrial appendage in patients with nonvalvular atrial fibrillation. OBJECTIVES: The aim of this analysis was to evaluate outcomes through 1 year with the Amulet occluder in the EMERGE LAA postapproval study. METHODS: Patients with commercial Amulet occluder implantation attempts between August 14, 2021, and December 15, 2023, and entered into the National Cardiovascular Data Registry LAAO (Left Atrial Appendage Occlusion) Registry were included. The safety endpoint composite included all-cause death, ischemic stroke, systemic embolism, and device- or procedure-related events requiring open cardiac surgery or endovascular intervention between device implantation and 7 days or hospital discharge (whichever was later). Major adverse events were also reported through 1 year and stratified by operator experience and prior LAAO attempt. RESULTS: A total of 12,180 patients underwent attempted Amulet occluder implantation (median follow-up 1 year (Q1-Q3: 1-1 year). Implantation success was 96.0% (11,693 of 12,180) (88.9% [353 of 397] in patients with prior failed LAAO attempts) with clinically relevant closure (peridevice leak ≤3 mm) achieved in 97.2% of patients (4,293 of 4,418) at 45 days postprocedure. A safety endpoint composite event occurred in 0.9% of patients (112 of 12,180). Any major adverse event through 45 days decreased with increased operator experience (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Kansas City Heart Rhythm Institute and Research Foundation, Overland Park, Kansas, USA. Electronic address: dhanunjaya.lakkireddy@hcahealthcare.com.
- University of Chicago, Chicago, Illinois, USA.
- CHI Creighton University School of Medicine - Bergan Mercy Hospital, Omaha, Nebraska, USA.
- Vanderbilt Heart Institute, Nashville, Tennessee, USA.
- Arizona Heart Arrhythmia Associates, Phoenix, Arizona, USA.
- Heart and Vascular Center, Essentia Health, Duluth, Minnesota, USA.
Förderung
- Abbott Laboratories
Zitieren
APA
Lakkireddy, D., Shah, A. P., Agarwal, H., Ellis, C. R., Makkar, A., Coylewright, M., Anderson, J. A., Gage, R., Alkhouli, M., & Freeman, J. V. (2026). 1-Year Real-World Outcomes With the Amulet Occluder From the EMERGE LAA Postapproval Study. JACC: Cardiovascular Interventions, 19(9), 1139-1151. https://doi.org/10.1016/j.jcin.2026.02.016
Vancouver
Lakkireddy D, Shah AP, Agarwal H, Ellis CR, Makkar A, Coylewright M, et al. 1-Year Real-World Outcomes With the Amulet Occluder From the EMERGE LAA Postapproval Study. JACC: Cardiovascular Interventions. 2026;19(9):1139-1151. doi:10.1016/j.jcin.2026.02.016
BibTeX
@article{Lakkireddy2026,
author = {Lakkireddy, Dhanunjaya and Shah, Atman P and Agarwal, Himanshu and Ellis, Christopher R and Makkar, Akash and Coylewright, Megan and Anderson, Jordan A and Gage, Ryan and Alkhouli, Mohamad and Freeman, James V},
title = {1-Year Real-World Outcomes With the Amulet Occluder From the EMERGE LAA Postapproval Study},
journal = {JACC: Cardiovascular Interventions},
year = {2026},
volume = {19},
number = {9},
pages = {1139--1151},
doi = {10.1016/j.jcin.2026.02.016}
}
EUVIMED